跳转至内容
Merck
CN

Y0001578

西地那非

European Pharmacopoeia (EP) Reference Standard

别名:

西地那非 柠檬酸盐, 1-[[3-(4,7-二氢-1-甲基-7-氧代-3-丙基-1H-吡唑并[4,3-d]嘧啶-5-基)-4-乙氧基苯基]磺酰基]-4-甲基哌嗪 柠檬酸盐, 5-[2-乙氧基-5-(4-甲基哌嗪-1-基)磺酰基苯基] -1-甲基-3-丙基-4H-吡唑并[5,4-e]嘧啶-7-酮 柠檬酸盐, UK-92,480, 西地那非

登录 查看组织和合同定价。

选择尺寸


关于此项目

经验公式(希尔记法):
C22H30N6O4S ·C6H8O7
化学文摘社编号:
分子量:
666.70
NACRES:
NA.24
PubChem Substance ID:
UNSPSC Code:
41116107
MDL number:
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

产品名称

西地那非, European Pharmacopoeia (EP) Reference Standard

InChI

1S/C22H30N6O4S.C6H8O7/c1-5-7-17-19-20(27(4)25-17)22(29)24-21(23-19)16-14-15(8-9-18(16)32-6-2)33(30,31)28-12-10-26(3)11-13-28;7-3(8)1-6(13,5(11)12)2-4(9)10/h8-9,14H,5-7,10-13H2,1-4H3,(H,23,24,29);13H,1-2H2,(H,7,8)(H,9,10)(H,11,12)

SMILES string

OC(=O)CC(O)(CC(O)=O)C(O)=O.CCCc1nn(C)c2C(=O)NC(=Nc12)c3cc(ccc3OCC)S(=O)(=O)N4CCN(C)CC4

InChI key

DEIYFTQMQPDXOT-UHFFFAOYSA-N

grade

pharmaceutical primary standard

API family

sildenafil

manufacturer/tradename

EDQM

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

2-8°C

Gene Information

human ... PDE5A(8654)

正在寻找类似产品? 访问 产品对比指南

Application

西地那非柠檬酸盐EP参考标准品的预期用途是欧洲药典规定的实验室测试。

Biochem/physiol Actions

西地那非是cGMP特异性5型磷酸二酯酶(PDE5)的一种有效选择性抑制剂。西地那非可用于治疗勃起功能障碍和肺动脉高压。
西地那非是cGMP特异性5型磷酸二酯酶(PDE5)的一种有效选择性抑制剂。西地那非可用于治疗勃起功能障碍和肺动脉高压。NO可激活鸟苷酸环化酶,从而导致cGMP水平增加并产生平滑肌松弛。西地那非可通过抑制负责cGMP降解的PDE5来增强NO的作用。

General description

本品按现行药典规定交付。所有为支持本产品而提供的信息,包括SDS和任何产品信息单均由药典颁发机构制定并发布。如需进一步信息和支持,请访问现行药典网站。

Other Notes

可能适用相应的销售限制。

Packaging

本品按照现行药典要求提供。有关当前单位数量,请见EDQM 参考目录

pictograms

Exclamation mark

signalword

Warning

Hazard Classifications

Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3

target_organs

Respiratory system

存储类别

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable


历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our 文件 section.

如需帮助,请联系 客户支持

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Lisa Nivison-Smith et al.
Experimental eye research, 128, 43-56 (2014-09-23)
Sildenafil, the active ingredient in Viagra, has been reported to cause transient visual disturbance from inhibition of phosphodiesterase 6 (PDE6), a key enzyme in the visual phototransduction pathway. This study investigated the effects of sildenafil on the rd1(+/-) mouse, a
Jing Peng et al.
Urology, 84(6), 1389-1394 (2014-10-13)
To evaluate the results of nocturnal penile erection test and response to daily sildenafil in patients with erectile dysfunction (ED) due to pelvic fracture urethral disruption. From January 2010 to January 2012, we included 38 patients with ED due to
M Paranjpe et al.
International journal of pharmaceutics, 476(1-2), 41-49 (2014-09-28)
For the development of any colloidal system, thorough characterization is extremely essential. This article discusses the physicochemical characterization of sildenafil-loaded solid lipid nanoparticle dispersions (SLN) including stability analysis over 6 months time period for possible pulmonary administration for the treatment
U Ozturk et al.
Irish journal of medical science, 183(3), 449-453 (2013-11-06)
It has been shown on experimental rat models that type 5-phosphodiesterase isoenzyme (PDE5) inhibitors have anti-fibrotic effects for Peyronie's disease (PD); however, this issue has not been addressed clinically. The aim of this study was to document the effects of
M W Helmy et al.
Journal of physiology and pharmacology : an official journal of the Polish Physiological Society, 65(3), 393-399 (2014-06-17)
Although the protective role of either nitric oxide (NO) or endothelin (ET) receptors modulation on the severity of cisplatin-induced nephrotoxicity has been recognized in previous studies including our own, the possible interaction between the two pathways remains obscure. In this

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持